Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Published:2019-01 Issue:1 Volume:30 Page:44-56
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Chan T.A.,Yarchoan M.,Jaffee E.,Swanton C.,Quezada S.A.,Stenzinger A.,Peters S.

Funder

NIH

NCI Cancer Center Support

Mellnikoff Precision Immunotherapy Kidney Cancer Fund

Exelixis, Merck, and Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/1/44/27511416/mdy495.pdf

Reference106 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

3. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

4. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet,2016

5. Nivolumab plus ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2013

Cited by 1865 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SLC2A3 is a Potential Factor for Head and Neck Squamous Cancer Development through Tumor Microenvironment Alteration;Current Gene Therapy;2025-04

2. Construction and validation of a TAMRGs prognostic signature for gliomas by integrated analysis of scRNA and bulk RNA sequencing data;Brain Research;2025-01

3. Comprehensive pan-cancer analysis unveils the significant prognostic value and potential role in immune microenvironment modulation of TRIB3;Computational and Structural Biotechnology Journal;2024-12

4. Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer;Biomedicine & Pharmacotherapy;2024-10

5. Comprehensive analysis of LD-related genes signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma;BMC Nephrology;2024-09-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3